Beta‐adrenergic receptor polymorphism in human cardiovascular disease

References

• Johnson JA, Terra SG. 3-Adrenergic receptor polymorph-isms: cardiovascular disease associations and pharmaco-genetics. Pharm Res 2002;19:1779–87.
   Google Scholar
• Rathz DA, Brown KM, Kramer LA, Liggett SB. Amino acid 49 polymorphism of the human 31-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39:155–60.
   Google Scholar
• Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human 32-adrenergic receptor. J Biol Chem 1999274:12670–4.
   Google Scholar
• Sandilands AJ, O'Shaughnessy KM, Brown MJ. Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 31-adrenoceptors versus G1y389 31-adreno-ceptors in isolated human atrial myocardium. Br J Pharmacol 2003;138:386–92.
   Google Scholar
• Molenaar P, Rabnott G, Yang I, Fong KM, Savarimuthu SM, Li L, et al. Conservation of the cardiostimulant effects of (-)-norepinephrine across Ser49Gly and Gly389Arg betar adrenergic receptor polymorphisms in human right atrium in vitro. J Am Coll Cardiol 2002;40:1275–82.
   Google Scholar
• Ryden M, Hoffstedt J, Eriksson P, Bringman S, Amer P. The Arg389Gly 31-adrenergic receptor gene polymorphism and human fat cell lipolysis. Int J Obesity 2001;25: 1599–603.
   Google Scholar
• Xie H-G, Dishy V, Sofowora G, Kim RB, Landau R, Smiley RM, et al. Arg389Gly [betah-adrenoceptor polymorphism varies in frequency among different ethic groups but does not alter response in vivo. Pharmacogenetics 2001;11: 191–7.
   Google Scholar
• &Ascher R, Belger H, Eilmes KJ, Tellkamp R, Radke J, Dhein S, et al. In-vivo studies do not support a major functional role for the Gly389Arg 31-adrenoceptor polymorphism in humans. Pharmacogenetics 2001;11:199–205.
   Google Scholar
• Dishy V, Sofowora G, Xie HG, Harris P, Wood A JJ, Stein CM. Arg389Gly beta-1 adrenoceptor polymorphism does not affect agonist-mediated responses in vivo. Clin Pharmacol Ther 2001;69:P5 (abstract).
   Google Scholar
• LaRosee K, Huntgeburth M, Rosenkranz S, Schnabel P. Arg389Gly-Polymorphismus des 31-Adrenozeptors: Unter-schiedliche Effekte von Metoprolol in Abhängigkeit vom Genotyp. Z Kardiol 2003;92 (Suppl):I/191 (abstract).
   Google Scholar
• O'Shaugnessy KM, Fu B, Dickerson C, Thurston D, Brown M J. The gain-of-function G389R variant of the 31-adreno-ceptor does not influence blood pressure or heart rate response to 3-blockade in hypertensive subjects. Clin Sci 200009:233–8.
   Google Scholar
• Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA, et al. A common 31-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to 3-blockade. Clin Pharmacol Ther 2003;73:366–71.
   Google Scholar
• Humma LM, Puckett BJ, Richardson HE, Terra SG, Andrisin TE, Lejeune BL, et al. Effects of betaradrenoceptor genetic polymorphisms on resting hemodynamics in patients under-going diagnostic testing for ischemia. Am J Cardiol 2001;88: 1034–7.
   Google Scholar
• Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Rastam L, et al. Polymorphisms in the pk-adrenergic receptor gene and hypertension. Circulation 2001; 104:187–90.
   Google Scholar
• Tesson F, Charron P, Peuchmaurd M, Nicaud V, Cambien F, Tiret L, et al for the CARDIGENE group. Characterization of a unique genetic variant of the 31-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol 1999;31:1025–32.
   Google Scholar
• Podlowski S, Wenzel K, Luther HP, Muller J, Bramlage P, Baumann G, et al. 31-Adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med 2000;78: 87–93.
   Google Scholar
• Iwai C, Akita H, Shiga N, Takai E, Miyamoto Y, Shimizu M, et al. Suppressive effect of the G1y389 allele of the beta1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. Circ J 2002;66:723–8.
   Google Scholar
• Small KM, Wagoner LE, Levin AM, Kardia SLR, Liggett SB. Synergistic polymorphisms of 32- and c2c-adrenergic recep-tors and the risk of congestive heart failure. N Engl J Med 2002;347: 1135–42.
   Google Scholar
• White HL, Maqbool A, McMahon AD, Yates L, Ball SG, Hall AS, et al. An evaluation of the beta-1 adrenergic receptor ARg389G1y polymorphism in individuales at risk of coronary events. A WOSCOPS substudy. Eur Heart J 2002;23:1087–92.
   Google Scholar
• Kanki H, Yang P, Xie HG, Kim RB, George AL, Jr, Roden DM. Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol 2002;13:252–6.
   Google Scholar
• Börjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in the gene coding for the betar adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000;21:1853–8.
   Google Scholar
• McNamara DM, MacGowan GA, London B. Clinical importance of b-adrenoceptor polymorphisms in cardiovas-cular disease. Am J Pharmacogenomics 2002;2:73–8.
   Google Scholar
• Green SA, Cole G, Jacinto M, Innes M, Liggett SB. A polymorphism of the human 32-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993;268: 23116–21.
   Google Scholar
• Green SA, Rathz DA, Schuster AJ, Liggett SB. The Ile164 32-adrenoceptor polymorphism alters salmoterol exosite binding and conventional agonist coupling to G. Eur J Pharmacol 2001;421:141–7.
   Google Scholar
• Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, et al. The Ile164 32-adrenergic receptor polymorphisms adversely affects the outcome of congestive heart failure. J Clin Invest 1998;102:1534–9.
   Google Scholar
• Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB. Myocardial signalling defects and impaired cardiac function of a human 32-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA 199603: 10483–8.
   Google Scholar
• Brodde O-E, Biischer R, Tellkamp R, Radke J, Dhein S, Insel PA. Blunted cardiac responses to receptor activation in subjects with Thr164Ile 32-adrenoceptors. Circulation 2001; 103:1048–50.
   Google Scholar
• Hoffstedt J, Iliadou A, Pedersen NL, Schalling M, Amer P. The effect of the beta2 adrenoceptor gene Thr164Ile poly-morphism on human adipose tissue lipolytic function. Br J Pharmacol 2001;133: 708–12.
   Google Scholar
• Bruck H, Leineweber K, Ulrich A, Radke J, Heusch G, Philipp T, et al. The Thr164Ile polymorphism of the human 32-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo. Am J Physiol Heart Circ Physiol 2003. Jul 17 [online 10.1152/ajpheart.00324.2003].
   Google Scholar
• Bruck H, Leineweber K, Beilfufg A, Weber M, Heusch G, Philipp T, et al. Genotype-dependent time course of lympho-cyte 132-adrenergic receptor down-regulation. Clin Pharmacol Ther 2003;74:255–63.
   Google Scholar
• Bruck H, Leineweber K, Biischer R, Ulrich A, Radke J, Insel PA, et al. The Gln27Glu 132-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo. Pharmacogenetics 2003;13:59–66.
   Google Scholar
• Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, et al. Beta-2 adrenergic receptor variants affect resting blood pessure and agonist-induced vasodilation in young adult Caucasians. Hypertension 1999;33:1425–30.
   Google Scholar
• Hoit BD, Suresh DP, Craft L, Walsh RA, Liggett SB. Beta2-adrenergic receptor polymorphisms at amino acid 16 differ-entially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 2000;139: 537–42.
   Google Scholar
• Cockroft JR, Gazis AG, Cross DJ, Wheatley A, Dewar J, Hall IP, et al. 132-Adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 2000;36:371–5.
   Google Scholar
• Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitiza-tion. N Engl J Med 2001;345:1030–5.
   Google Scholar
• Garovic VD, Joyner MJ, Dietz NM, Boerwinkle E, Turner ST. 132-Adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J Physiol 2003;546.2:583–9.
   Google Scholar
• Green SA, Turki J, Innes M, Liggett SB. Amino-terminal polymorphisms of the human 132-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994;33:9414–9.
   Google Scholar
• Liggett SB. Polymorphisms of the 132-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997;156:S156–62.
   Google Scholar
• Dewar JC, Wilkinson J, Wheatley A, Thomas NS, Doull I, Morton N, et al. The glutamine 27 112 adrenoceptor poly-morphism is associated with elevated immunglobulin E levels in asthmatic families. J Allergy Clin Immunol 1997;100:261–5.
   Google Scholar
• Xie H-G, Stein CM, Kim RB, Gainer JV, Sofowora G, Dishy V, et al. Human 132-adrenergic receptor polymorphisms: No association with essential hypertension in black and white Americans. Clin Pharmacol Ther 2000;67: 670–5.
   Google Scholar
• Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promotor and coding region 132-adrenergic receptor haplotypes alter receptor ex-pression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000;97:10483–8.
   Google Scholar
• Bengtsson K, Orho-Melander M, Melander O, Lindbald U, Ranstam J, Rastam L, et al. 132-Adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension 2001;37:1303–8.
   Google Scholar
• Fenech A, Hall IP. Pharmacogenetics of asthma. Br J Clin Pharmacol 2001;53:3–15.
   Google Scholar
• Joos L, Sandford A J. Genotype predictors of response to asthma medications. Curr Opin Pulm Med 2002;8:9–15.
   Google Scholar